J Korean Diabetes JKD The Journal of Korean Diabetes 2233-7431 Korean Diabetes Association 10.4093/jkd.2018.19.1.35 Focused Issue Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association Kim Hyun Jin Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. Corresponding author: Hyun Jin Kim. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, 266 Munhwa-ro, Jung-gu, Daejeon 35015, Korea, kimhj43@cnuh.co.kr 03 2018 27 03 2018 19 1 35 40 28 01 2018 02 02 2018 Copyright © 2018 Korean Diabetes Association 2018 Korean Diabetes Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy, which was a change from the previous guideline that recommended them only as a combination therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) have demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RAs may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

 Cardiovascular diseases Diabetes mellitus Glucagon-like peptide-1 receptor agonist Hypoglycemia Obesity Practice guideline Ko SH Hur KY Rhee SY Kim NH Moon MK Park SO Lee BW Kim HJ Choi KM Kim JH; Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association Diabetes Metab J 2017 41 337 348 Kim HJ Park SO Ko SH Rhee SY Hur KY Kim NH Moon MK Lee BW Kim JH Choi KM Committee of Clinical Practice Guidelines of the Korean Diabetes Association Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus: a position statement of the Korean Diabetes Association Diabetes Metab J 2017 41 423 429 Nauck MA Meier JJ Cavender MA Abd El Drucker DJ Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Circulation 2017 136 849 870 Thrasher J Pharmacologic management of type 2 diabetes mellitus: available therapies Am J Med 2017 130 6S S4 17 Madsbad S Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists Diabetes Obes Metab 2016 18 317 332 Monami M Dicembrini I Marchionni N Rotella CM Mannucci E Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis Exp Diabetes Res 2012 2012 672658 Domecq JP Prutsky G Leppin A Sonbol MB Altayar O Undavalli C Wang Z Elraiyah T Brito JP Mauck KF Lababidi MH Prokop LJ Asi N Wei J Fidahussein S Montori VM Murad MH Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis J Clin Endocrinol Metab 2015 100 363 370 Pfeffer MA Claggett B Diaz R Dickstein K Gerstein HC Køber LV Lawson FC Ping L Wei X Lewis EF Maggioni AP McMurray JJ Probstfield JL Riddle MC Solomon SD Tardif JC; Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 2015 373 2247 2257 Marso SP Daniels GH Brown-Frandsen K Kristensen P Mann JF Nauck MA Nissen SE Pocock S Poulter NR Ravn LS Steinberg WM Stockner M Zinman B Bergenstal RM Buse JB LEADER Steering Committee Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 2016 375 311 322 Marso SP Bain SC Consoli A Eliaschewitz FG Jódar E Leiter LA Lingvay I Rosenstock J Seufert J Warren ML Woo V Hansen O Holst AG Pettersson J Vilsbøll T; Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 2016 375 1834 1844 Garber A Henry RR Ratner R Hale P Chang CT Bode B LEAD-3 (Mono) Study Group Liraglutide, a oncedaily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes Metab 2011 13 348 356 Umpierrez G Tofé Povedano S Pérez Manghi F Shurzinske L Pechtner V Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes Care 2014 37 2168 2176 Cimmaruta D Maiorino MI Scavone C Sportiello L Rossi F Giugliano D Esposito K Capuano A Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review Expert Opin Drug Saf 2016 15 Suppl 2 77 83 Diamant M Nauck MA Shaginian R Malone JK Cleall S Reaney M de Vries D Hoogwerf BJ MacConell L Wolffenbuttel BH 4B Study Group Glucagonlike peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes Diabetes Care 2014 37 2763 2773 Yoon KH Hardy E Han J Exenatide versus insulin lispro added to basal insulin in a subgroup of Korean patients with type 2 diabetes mellitus Diabetes Metab J 2017 41 69 74 Mathieu C Rodbard HW Cariou B Handelsman Y Philis-Tsimikas A Ocampo Francisco AM Rana A Zinman B BEGIN: VICTOZA ADD-ON (NN1250-3948) study group A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON) Diabetes Obes Metab 2014 16 636 644 Pozzilli P Norwood P Jódar E Davies MJ Ivanyi T Jiang H Woodward DB Milicevic Z Placebo-controlled, randomized trial of the addition of once-weekly glucagonlike peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9) Diabetes Obes Metab 2017 19 1024 1031 Russell-Jones D Vaag A Schmitz O Sethi BK Lalic N Antic S Zdravkovic M Ravn GM Simó R Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 2009 52 2046 2055 Zinman B Gerich J Buse JB Lewin A Schwartz S Raskin P Hale PM Zdravkovic M Blonde L; Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) Diabetes Care 2009 32 1224 1230 Wysham C Blevins T Arakaki R Colon G Garcia P Atisso C Kuhstoss D Lakshmanan M Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care 2014 37 2159 2167 Nauck M Weinstock RS Umpierrez GE Guerci B Skrivanek Z Milicevic Z Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) Diabetes Care 2014 37 2149 2158 Abd El Kahle M Meier JJ Nauck MA A metaanalysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients Diabetes Obes Metab 2017 19 216 227 GLP-1 receptor agonists for patients with type 2 diabetes mellitus

Adapted from the article of Ko et al. Diabetes Metab J 2017;41:337-48 [1].

HbA1c, glycosylated hemoglobin; GLP-1, glucagon-like peptide-1; SC, subcutaneous; GI, gastrointestinal; MEN2, multiple endocrine neoplasia 2; MTC, medullary thyroid cancer.

aMonotherapy.